OTCMKTS:IMUC EOM Pharmaceuticals (IMUC) Stock Price, News & Analysis → 😱 This phenomenon is smashing regular market gains (From MillPub) (Ad) Free IMUC Stock Alerts $0.20 0.00 (0.00%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$0.16▼$0.2050-Day Range$0.11▼$0.3052-Week Range$0.11▼$0.40Volume392 shsAverage Volume3,695 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get EOM Pharmaceuticals alerts: Email Address Ad MillPub😱 This phenomenon is smashing regular market gainsThanks to a little-known “Pathfinder” trading phenomenon… Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading. At every single market open.Click here to save your seat and join the next LIVE workshop! About EOM Pharmaceuticals Stock (OTCMKTS:IMUC)Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.Read More IMUC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMUC Stock News HeadlinesJanuary 5, 2024 | uk.finance.yahoo.comImmunoCellular Therapeutics, Ltd. (IMUC)December 29, 2023 | wsj.comEOM Pharmaceutical Holdings Inc.May 1, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. November 7, 2023 | finance.yahoo.comEOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613November 4, 2023 | markets.businessinsider.comIZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 YearsNovember 3, 2023 | msn.comImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives RevenuesNovember 1, 2023 | morningstar.comOramed Pharmaceuticals Inc ORMPOctober 11, 2023 | markets.businessinsider.comAnalyst Ratings for Olema PharmaceuticalsMay 1, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. September 6, 2023 | finance.yahoo.comEOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in BrazilAugust 17, 2023 | uk.finance.yahoo.comQ2 2023 PAVmed Inc Earnings CallAugust 3, 2023 | msn.comEOM Pharmaceuticals shelves plans to uplist shares, raise $15MJuly 17, 2023 | benzinga.comAcumen Pharmaceuticals Announces Proposed Public Offering of Common StockJuly 3, 2023 | marketwatch.comAmneal Pharmaceuticals: FDA Requests Additional Information on IPX203 IngredientJune 14, 2023 | marketwatch.comAmneal Pharmaceuticals Gets FDA Approval for Injectable Tumor TreatmentMay 16, 2023 | msn.comTrade commission fights Amgen's $28B purchase of Horizon TherapeuticsMay 10, 2023 | msn.comPharma CEOs to testify in U.S. Senate hearing on insulin pricesMay 10, 2023 | marketwatch.com8-K: Acumen Pharmaceuticals, Inc.May 9, 2023 | msn.comOlema Pharmaceuticals GAAP EPS of -$0.70 misses by $0.04May 9, 2023 | investing.comOliX Pharmaceuticals Inc (226950)March 30, 2023 | msn.comUSFDA gives final nod to Alembic Pharmaceuticals’ Glaucoma drugMarch 27, 2023 | reuters.comU.S. Supreme Court mulls Amgen bid to revive cholesterol drug patentsMarch 13, 2023 | marketwatch.comRegeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gainsMarch 11, 2023 | finance.yahoo.comEOM Pharmaceuticals Holdings, Inc. (IMUC)February 24, 2023 | seekingalpha.comIonis Pharmaceuticals, Inc. (IONS) Q4 2022 Earnings Call TranscriptDecember 8, 2022 | technews.tmcnet.comAltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological DiseasesNovember 29, 2022 | marketwatch.comAlaunos Therapeutics Shares Drop 24% After Public Offering PricesSee More Headlines Receive IMUC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EOM Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2018Today5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:IMUC CUSIPN/A CIK822411 Webwww.imuc.com Phone(201) 351-0605Fax818-224-5287Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.37 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Irach B. Taraporewala B.S. (Age 68)M.S., Ph.D., CEO, President & Director Comp: $265.65kMr. Wayne I. Danson CPA (Age 70)CFO & Treasurer Comp: $150kMr. Eli Goldberger (Age 34)Founder, Chairman & COO Dr. Shalom Z. Hirschman M.D. (Age 88)Co-Founder, Chief Scientific Officer & Medical Director Key CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors IMUC Stock Analysis - Frequently Asked Questions How have IMUC shares performed in 2024? EOM Pharmaceuticals' stock was trading at $0.2320 at the beginning of the year. Since then, IMUC shares have decreased by 14.7% and is now trading at $0.1979. View the best growth stocks for 2024 here. Are investors shorting EOM Pharmaceuticals? EOM Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 400 shares, an increase of 300.0% from the March 31st total of 100 shares. Based on an average trading volume of 7,500 shares, the days-to-cover ratio is currently 0.1 days. View EOM Pharmaceuticals' Short Interest. How were EOM Pharmaceuticals' earnings last quarter? EOM Pharmaceuticals Holdings, Inc. (OTCMKTS:IMUC) issued its earnings results on Monday, August, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter. How do I buy shares of EOM Pharmaceuticals? Shares of IMUC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IMUC) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EOM Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
